Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06940232 · ClinicalTrials.gov registry record

Validating a Blood Test for the Detection of Traumatic Brain Injury in Children

A clinical trial of Pediatric Traumatic Brain Injury, sponsored by University of Nebraska.

Recruiting
Registry status
330
Enrollment target
1
Study location

NCT06940232 is a study of Pediatric Traumatic Brain Injury that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 330 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06940232, a study of Pediatric Traumatic Brain Injury, is actively recruiting participants, sponsored by University of Nebraska.

RECRUITING
Registry status
330 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to establish if Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) are predictive of computed tomography (CT) findings in pediatric traumatic brain injuries (TBI). The participant population is pediatric patients, ages 0 to less than 18 years old with a possible TBI or trauma-related injury who have blood drawn per standard of care in the emergency department. Blood samples will be analyzed using the i-STAT TBI cartridge (Abbott Laboratories, Abbott Park, IL, USA) by the Emergency Department charge nurse within one hour of collection of the blood sample. Clinical outcomes will be assessed via telephone interview with a parent at 3 and 6 months for all surviving TBI patients.

Interventions

  • DIAGNOSTIC_TEST Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers

Study Locations (1)

Nebraska

  • Children's Nebraska - Omaha

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2025-05-14
Est. Completion 2027-12

Sponsor

University of Nebraska

407 total trials

What the Registry Record Tells You About NCT06940232

The ClinicalTrials.gov registry entry for NCT06940232 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pediatric Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers is the first listed.

NCT06940232 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT06940232 about?

NCT06940232 is a clinical study titled "Validating a Blood Test for the Detection of Traumatic Brain Injury in Children". The primary objective of this study is to establish if Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) are predictive of computed tomography (CT) findings in pediatric traumatic brain injuries (TBI). The participant population is pediatric patients, ages 0 to le...

What is the current status of trial NCT06940232?

This trial is currently recruiting. The enrollment target is 330 participants. The study started on 2025-05-14. Estimated completion is 2027-12.

What conditions does trial NCT06940232 study?

This clinical trial studies the following conditions: Pediatric Traumatic Brain Injury.

What interventions are being tested in trial NCT06940232?

The interventions under investigation include: Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06940232?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06940232 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.